Drug Trial Radar · NCT04162210
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
325
Actual
Start
Apr 2, 2020
Primary completion
Sep 12, 2022
Study completion Mar 11, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.
Conditions
- Multiple Myeloma
Interventions
Belantamab mafodotinDrug
Belantamab mafodotin will be administered.
Pom/dex (Pomalidomide plus low dose Dexamethasone)Drug
Pomalidomide and Dexamethasone will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)Time frame: Up to 27 months
Locations
136 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Pueblo, Colorado
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Clifton Park, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Corvallis, Oregon
GSK Investigational Site
Eugene, Oregon
GSK Investigational Site
Tyler, Texas
GSK Investigational Site
Milwaukee, Wisconsin
GSK Investigational Site
St Albans, Australia
GSK Investigational Site
Gosford NSW, New South Wales, Australia
GSK Investigational Site
Liverpool, New South Wales, Australia
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Woodville, South Australia, Australia
GSK Investigational Site
Hobart, Tasmania, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Geelong, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Bruges, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Kortrijk, Belgium
GSK Investigational Site
Yvoir, Belgium
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
Fortaleza, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Pleven, Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.